Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ophthalmic Solution Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
T4090 0.2%, T4090 0.3%, Rhopressa®
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
24
States / cities
Glendale, Arizona • Glendale, California • Inglewood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844-Cl, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Mission Hills, California • Newport Beach, California • Largo, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced May 22, 2026, 4:46 AM EDT
Withdrawn Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Retinal Disorder
Interventions
Placebos, ZA Low dose, ZA high dose
Drug
Lead sponsor
Retinagenix Holdings
Industry
Eligibility
6 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced May 22, 2026, 4:46 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Dry Eye
Interventions
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced May 22, 2026, 4:46 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 4:46 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cataract
Interventions
Brimonidine Purite
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
4
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced May 22, 2026, 4:46 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Corneal Dystrophy, Band-Shaped
Interventions
EDTA Eye Drops
Drug
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Ocular Redness
Interventions
Placebo, Brimonidine tartrate 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
40 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
NS2, Prednisolone acetate ophthalmic suspension (1%)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Lancaster, California • Golden, Colorado • Hamden, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Glendale, California • Rancho Cordova, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced May 22, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced May 22, 2026, 4:46 AM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure
Interventions
Nanodropper
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Latanoprostene bunod
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
20 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced May 22, 2026, 4:46 AM EDT
Not yet recruiting Phase 3 Interventional
View directory record Official record
Conditions
Ocular Hyperemia
Interventions
Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
19 Years to 99 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Week to 5 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced May 22, 2026, 4:46 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Asteroid Hyalosis
Interventions
C-KAD Ophthalmic Solution
Drug
Lead sponsor
Chakshu Research, Inc.
Industry
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%, Placebo Comparator
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced May 22, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced May 22, 2026, 4:46 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Inflammation, Uveitis
Interventions
Laquinimod eye drops
Drug
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced May 22, 2026, 4:46 AM EDT